文献速递治疗药物监测与药物基因组学特殊人群用药

体外膜肺氧合中氧合器前后万古霉素浓度的药代动力学评估:前瞻性观察研究

Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

该前瞻性观察研究纳入8例接受静脉-动脉体外膜肺氧合(VA-ECMO)的成人患者,采集氧合器前后万古霉素浓度共64份,构建三室模型评估ECMO流量对万古霉素清除的影响。结果显示ECMO流量(3500-5000 mL/min)不影响万古霉素清除,万古霉素未被ECMO回路 sequestration,常见给药方案常导致疗效不足或毒性过高,建议个体化治疗药物监测。

要点

  • ECMO流量在3500-5000 mL/min范围内不影响万古霉素清除。
  • 万古霉素未被ECMO回路 sequestration。
  • 常见万古霉素方案常致疗效不足或毒性过高,推荐个体化TDM。

核心结论

  • ECMO流量在3500-5000 mL/min范围内不影响万古霉素清除,万古霉素未被ECMO回路 sequestration。
  • 常见万古霉素方案常导致疗效不足和/或毒性过高,推荐ECMO患者进行个体化治疗药物监测。

研究设计与样本

  • 前瞻性观察研究,纳入2016年12月1日至2017年10月1日期间接受万古霉素和VA-ECMO的成人患者8例,共采集64份血清浓度。
  • 收集每例患者的ECMO设置及四组氧合器前后万古霉素浓度,构建房室模型评估ECMO流量对万古霉素清除和回路 sequestration 的影响。
  • 采用贝叶斯后验浓度计算每例患者氧合器前后浓度,汇总药代动力学参数,并基于最终模型进行疗效和毒性预测模拟。

主要发现

  • 患者中位年龄58.5岁(IQR 50.8-62.3),计算肌酐清除率39 mL/min(IQR 29.5-62.5),ECMO流量3980 mL/min(IQR 3493.75-4132.5)。
  • 三室模型最佳拟合数据(贝叶斯:氧合前血浆R2=0.99,氧合后R2=0.99)。
  • 万古霉素清除未受ECMO流量影响(p=0.7)。
  • 模拟显示万古霉素1 g每日两次对于MIC>0.5 mg/L很少足够。
  • 剂量≥1.5 g每日两次常超过毒性暴露阈值。

关键数值与推荐

  • 万古霉素清除未受ECMO流量影响(p=0.7)。
  • 模拟显示万古霉素1 g每日两次对于MIC>0.5 mg/L很少足够。
  • 剂量≥1.5 g每日两次常超过毒性暴露阈值。

临床怎么用

  • ECMO患者使用万古霉素时应进行个体化治疗药物监测。
  • 常见万古霉素方案可能疗效不足或毒性过高,需根据TDM调整剂量。

局限性

  • 样本量小(8例患者),结果需在更大样本中验证。
  • 仅纳入VA-ECMO患者,未涉及VV-ECMO等其他模式。
  • 研究期间ECMO流量范围有限(3500-5000 mL/min),超出此范围的结果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life support frequently utilized in catastrophic lung and or cardiac failure. Patients on ECMO often receive vancomycin therapy for treatment or prophylaxis against Gram-positive organisms. It is unclear if ECMO affects vancomycin pharmacokinetics, thus we modeled the pharmacokinetic behavior of vancomycin according to ECMO-specific variables. METHODS: Adult patients receiving vancomycin and Veno-Arterial-ECMO between 12/1/2016 and 10/1/2017 were prospectively enrolled. Extracorporeal membrane oxygenation settings and four sets of pre- and post-oxygenator vancomycin concentrations were collected for each patient. Compartmental models were built and assessed ECMO flow rates on vancomycin clearance and potential circuit sequestration. Bayesian posterior concentrations of the pre- and post-oxygenator concentrations were obtained for each patient, and summary pharmacokinetic parameters were calculated. Simulations were performed from the final model for efficacy and toxicity predictions. RESULTS: Eight patients contributed 64 serum concentrations. Patients were a median (interquartile range) age of 58.5 years (50.8-62.3) with a calculated creatinine clearance of 39 mL/min (29.5-62.5) and ECMO flow rates of 3980 mL/min (interquartile range = 3493.75-4132.5). A three-compartment model best fit the data (Bayesian: plasma pre-oxygenation R2 = 0.99, post-oxygenation R2 = 0.99). Vancomycin clearance was not impacted by ECMO flow rate (p = 0.7). Simulations demonstrated that vancomycin 1 g twice daily was rarely sufficient for minimum inhibitory concentrations > 0.5 mg/L. Doses ≥ 1.5 g twice daily often exceeded toxicity thresholds for exposure. CONCLUSIONS: Extracorporeal membrane oxygenation flow rates did not influence vancomycin clearance between flow rates of 3500 and 5000 mL/min and vancomycin was not sequestered in ECMO. Common vancomycin regimens resulted in suboptimal efficacy and/or excessive toxicity. Individual therapeutic drug monitoring is recommended for patients on ECMO.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Mahmoud AA, Avedissian SN, Al-Qamari A, et al. Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study. Clin Pharmacokinet. 2020. PMID: 32468446. doi:10.1007/s40262-020-00902-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。